(NASDAQ: MREO) Mereo Biopharma Group's forecast annual revenue growth rate of 543.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.14%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.28%.
Mereo Biopharma Group's revenue in 2026 is $500,000.On average, 9 Wall Street analysts forecast MREO's revenue for 2026 to be $27,275,173,517, with the lowest MREO revenue forecast at $0, and the highest MREO revenue forecast at $57,179,202,731. On average, 7 Wall Street analysts forecast MREO's revenue for 2027 to be $37,816,057,378, with the lowest MREO revenue forecast at $1,351,028,140, and the highest MREO revenue forecast at $87,434,913,005.
In 2028, MREO is forecast to generate $126,955,270,898 in revenue, with the lowest revenue forecast at $22,641,258,390 and the highest revenue forecast at $237,114,190,777.